Market News Archives

Amarin Corporation (NASDAQ: AMRN): Deep Value or Hidden Catalyst? ( $AMRN $IBB $XBI )

by Vista Partners LLC October 3, 2025 547Views 0Likes

Amarin Corporation (NASDAQ: AMRN), a company that envisions a world where cardiovascular disease is NOT the leading cause of death worldwide, seemingly presents itself as a deep-value opportunity, trading near its cash value yet is believed to be poised for a turnaround…

Virtual Health Giant Teladoc Rallies On Thursday After Snapping Up Acquisitions in ’25 – ( $TDOC $AMWL $DOCS $EVH )

by Vista Partners LLC October 2, 2025 688Views 0Likes

Teladoc Health (TDOC) shares are is surging today. On Aug, 14 Teledoc, the global leader in virtual care, announced an acquisition of Telecare, an Australian pioneer in virtual specialist and allied health services—a move celebrated by Wall Street as turbocharging Teladoc’s…

OpenAI Completes Record $6.6 Billion Share Sale, Becomes Most Valuable Private Company -( $META $NVDA $SFTBY $TSLA )

by Vista Partners LLC October 2, 2025 617Views 0Likes

OpenAI, the force behind ChatGPT, has shot to the top of the AI world with a record-breaking secondary share sale that now values the company at $500 billion— vaulting it past SpaceX to become the world’s largest startup. The transaction, finalized this…

Cantor Fitzgerald Analyst Report Highlights Eupraxia’s Market Potential Post Successful Funding – ( $EPRX $IBB $XBI )

by Vista Partners LLC October 1, 2025 649Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has catapulted into the biotech spotlight following an influential analyst report from Cantor Fitzgerald that reaffirmed its “Overweight” rating and set a robust $11 price target—nearly double the recent public offering price. This endorsement comes on the heels…

Eupraxia’s Diffusphere Tech Driving Growth And Interest: EOE Clinical Milestone and Big Public Offering

by John F. Heerdink, Jr. September 30, 2025 557Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) reported robust clinical results in its highest-dose cohort—8mg per injection—within the ongoing RESOLVE Phase 2b trial for patients with eosinophilic esophagitis (EoE). The pronounced tissue health improvements and eosinophil reduction in Cohort 9 prompted company advisors and safety…

Modular Medical Secures $4.4M Seeking to Fast-Track FDA Clearance and Launch Pivot Insulin Patch Pump -( $MODD $LLY $TNDM $MDT )

by John F. Heerdink, Jr. September 29, 2025 622Views 0Likes

Modular Medical (NASDAQ: MODD) has made a flurry of strategic moves and operational strides in recent weeks as it works to reshape the landscape of insulin delivery for millions living with diabetes. The company secured approximately $4.4 million in gross proceeds through…

Jennifer Garner’s Once Upon a Farm Files for NYSE IPO: Transforming Kids’ Nutrition with Farm-Fresh Values – ( $OFRM $GS $JPM $BAC )

by John F. Heerdink, Jr. September 29, 2025 793Views 0Likes

Once Upon a Farm, the organic baby and kids’ food pioneer co-founded by actress Jennifer Garner, officially filed for an initial public offering on the New York Stock Exchange this week, signaling a remarkable milestone for a brand that has fused celebrity…

Serina Therapeutics CEO: Why Now Is the Time to Invest in Biotech – ( $SER $IBB $XBI )

by John F. Heerdink, Jr. September 26, 2025 653Views 0Likes

In a video released this week, Serina Therapeutics' (NYSE American: SER) Chief Executive Officer Steven Ledger outlined what he described as a rare convergence of factors for biotech investing, highlighting both daunting market conditions and an emerging window of opportunity. Watch Now…

Palsonify FDA Greenlight: Crinetics Seeks to Launch Oral Therapy for Acromegaly Patients – ( $CRNX $IBB $XBI )

by John F. Heerdink, Jr. September 26, 2025 614Views 0Likes

San Diego, CA based Crinetics Pharmaceuticals (CRNX) delivered a watershed moment on Friday as the FDA granted approval of Palsonify (paltusotine), the first once-daily, oral therapy for acromegaly—a rare hormonal disorder—propelling shares to their strongest session of the year. On Friday, Crinetics…

Cantor Fitzgerald Analyst Report Drives Biotech Buzz About Eupraxia After Major Funding – ( $EPRX $IBB $XBI )

by John F. Heerdink, Jr. September 25, 2025 565Views 0Likes

Cantor Fitzgerald has recently updated their coverage of Eupraxia Pharmaceuticals (NASDAQ: EPRX) with an “Overweight” rating and an $11 target price—a move that places the emerging biotech on the radar of institutional investors seeking innovation in the field of locally delivered, extended-release…

Market News

Your Guide To Staying Informed In The Markets